China Money Network
Login
Join

Vivo Capital Leads $50M Series B Round In Chinese CRO Firm dMed Biopharmaceutical

  • October 16, 2019 — 17:50 CST

This Data Is Locked!

This area is available only to Subscribers.

dMed Biopharmaceutical Co., Ltd., a Chinese full service Clinical Contract Research Organization (CRO), announces on Wednesday that it has completed nearly US$50 million in a... [DATA LOCKED]

UNLOCK DATA

Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals

Join

Access Thousands of Data Points to Monitor Chinese Private Equity Deal Movement and Relationships

Already Have an Account?

Login
Related Topics:

Related Data: